Compare AbCellera Biologics Inc (ABCL) vs Canopy Growth Corp (CGC) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

CGC trades at $0.95, down 5% on the day, with a bearish technical signal and negative earnings momentum after recent quarterly misses. The company reported a net loss of $598.12 million in 2025, with a net income margin of -222.36%, though revenue trends show some stabilization. Cash flow remains negative, and the stock faces Nasdaq listing compliance risks due to its low price, with news highlighting potential for a reverse stock split.

The outlook is highly speculative with significant operational and financial risks. While valuation ratios like P/S of 1.44 and P/B of 0.83 appear modest, persistent losses and high debt levels overshadow any near-term upside. Investor sentiment is mixed among analysts, with a slight hold bias, but the path to profitability remains uncertain amid competitive and regulatory pressures.